Skip to main content

Table 1 Baseline characteristics by study and treatment group in women from the EPAT and WELL-HART trials

From: Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study

Characteristic

EPAT (n = 127)

 

WELL-HART (n = 105)

  
 

Placebo (n = 57)

ET (n = 70)

P

Placebo (n = 37)

ET (n = 34)

EPT (n = 34)

P*

P †

Age at baseline mammogram, years (mean ± SEM)

62.3 ± 1.0

60.2 ± 0.8

0.10

64.7 ± 1.0

61.8 ± 1.2

64.1 ± 1.1

0.15

0.005

Years since menopause at baseline (mean ± SEM)

15.1 ± 1.4

12.5 ± 1.0

0.12

18.6 ± 1.6

15.9 ± 1.4

19.5 ± 1.9

0.28

0.001

Number of deliveries (live and stillbirths) (mean ± SEM)

2.4 ± 0.2

2.3 ± 0.2

0.75

4.5 ± 0.6

3.6 ± 0.4

4.1 ± 0.5

0.47

0.0001

Race, n (%)

        

White, non-latina

34 (59.7)

40 (57.1)

 

12 (32.4)

7 (20.6)

14 (41.2)

  

Black, non-latina

6 (10.5)

10 (14.3)

 

4 (10.8)

10 (29.4)

5 (14.7)

  

Latina

10 (17.5)

13 (18.6)

 

20 (54.1)

9 (26.5)

11 (32.4)

  

Asian or Pacific Islander

7 (12.3)

7 (10.0)

0.91

1 (2.7)

8 (23.5)

4 (11.8)

0.01‡

0.0005

Education, n (%)

        

High school graduate or less

8 (14.0)

9 (12.9)

 

20 (54.1)

15 (44.1)

15 (44.1)

  

Trade or business school/some college

29 (50.9)

33 (48.6)

 

11 (29.7)

12 (35.3)

13 (38.2)

  

Bachelor's degree or more

20 (35.1)

27 (38.6)

0.92

6 (16.2)

7 (20.6)

6 (17.7)

0.90

0.0001

Family history of breast cancer (first-degree relative), n (%)

9 (15.8)

6 (8.6)

0.21

2 (5.4)

7 (20.6)

3 (8.8)

0.14‡

0.91

Age at menarche, years (mean ± SEM)

12.7 ± 0.2

12.6 ± 0.2

0.86

12.7 ± 0.3

12.8 ± 0.3

13.3 ± 0.3

0.32

0.21

Ever used postmenopausal hormones, n (%)

36 (63.2)

42 (60.0)

0.72

13 (35.1)

15 (44.1)

21 (61.8)

0.08

0.02

BMI, kg/m2 (mean ± SEM)

28.7 ± 0.7

28.7 ± 0.7

0.96

30.8 ± 1.0

31.4 ± 1.0

30.2 ± 1.1

0.73

0.007

Mammographic density at baseline, % (mean ± SEM)

17.8 ± 2.3

22.3 ± 1.9

0.13

7.9 ± 1.8

10.8 ± 2.1

13.3 ± 2.3

0.19

0.0001

  1. *Comparison of characteristics by treatment group, χ2 test for comparison of categorical variables, analysis of variance for comparison of means; †comparison of characteristics between trials (EPAT versus WELL-HART), χ2 test for comparison of categorical variables, analysis of variance for comparison of means; ‡Fisher's exact test. EPAT, Estrogen in the Prevention of Atherosclerosis Trial; ET, 1 mg/day micronized 17β-estradiol; EPT, 1 mg/day micronized 17β-estradiol with 5 mg/day medroxyprogesterone acetate for days 19 to 30 each month; WELL-HART, Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial.